Background: A desperate need for novel therapies in pediatric ependymoma (EPN) exists, as chemotherapy remains ineffective and radiotherapy often fails. EPN have significant infiltration of immune cells, which correlates with outcome. Immune checkpoint inhibitors provide an avenue for new treatments. This study characterizes tumor-infiltrating immune cells in EPN and aims at predicting candidates for clinical trials using checkpoint inhibitors targeting PD-L1/PD-1 (programmed death ligand 1/programmed death 1).
INTRODUCTION
Pediatric ependymoma (EPN) is the third most common central nervous system (CNS) tumor and these tumors usually arise from the lining of the ventricles of the CNS. 1 clinically distinct with data suggesting ST-RELA patients have a poorer outcome than those with YAP. 3 As is the case in all intracranial EPN, there is little evidence that chemotherapy benefits ST-RELA patients and treatment for these patients has remained stagnant with gross total resection and radiation as the standard of care. It is critical to develop new treatment strategies for these patients.
Immune checkpoint inhibitors, which overcome tumor associated immunosuppression, have proven effective in several adult tumors 4 and have become a particular interest in brain tumors. 5 One class of these inhibitors target the interaction of Programmed Death Ligand 1 (PD-L1) and its receptor programmed death 1(PD-1). PD-1 is expressed on antigen-activated T cells, B cells, natural killer cells, and often on tumor-infiltrating leukocytes, while its ligand, PD-L1 is normally expressed on dendritic cells, myeloid cells, and epithelial cells.
The PD-1/PD-L1 axis in physiologic conditions helps to mitigate and dampen the immune response to a stimulus. 6 In the context of tumors, PD-L1 is found on tumor cells and on infiltrating myeloid cells. As PD-1 and PD-L1 interact, T cells activity is diminished and they take on an exhausted phenotype. 7 Preventing this PD-L1/PD-1 interaction by a PD-1 inhibitor, such as pembroluzimab and nivolumab, has shown antitumor effects by reversing T-cell exhaustion. These agents are now approved in certain adult tumors, such as melanoma. 8 With respect to CNS tumors, there is evidence in adult glioblastoma that PD-1's interaction with PD-L1 contributes to the profound immunosuppression seen in this tumor. 5 Our lab has shown that EPNs have significant infiltration of immune cells. 9 We have also shown that the phenotype of these immune cells correlate with outcome and molecular subtypes in the tumor immune microenvironment of posterior fossa EPN 10 and therefore investigation of immune therapies in this tumor is particularly important.
Given that PD-L1 expression on patient tumors is a current predictive marker of response to PD-1 checkpoint blockade, 11 the aim of our current study was to evaluate supratentorial and posterior fossa EPN for PD-L1/PD-1. We examined PD-L1 transcript and protein expression levels across EPN supratentorial subtypes and posterior fossa subtypes. Flow cytometry was also utilized to identify which EPN microenvironment cell type expressed PD-L1 protein and to characterize the tumor-infiltrating immune cells. These studies may predict which patients with EPN will have a positive response to future clinical trials with PD-L1/PD-1 checkpoint inhibitors in pediatrics.
MATERIALS AND METHODS

Study approval
Primary patient tumor and normal brain samples were obtained from Children's Hospital Colorado and collected in accordance with local and federal human research protection guidelines and institutional review board regulations (COMIRB 95-500 and 09-0906). Informed consent was obtained for all specimens collected.
Transcriptomic analysis
The primary study cohort of EPN samples consists of: 20 primary Group A EPNs, 21 primary Group B EPNs, 9 recurrent Group A EPNs, 8 recurrent Group B EPNs, 11 ST-RELA EPNs, 2 ST-YAP EPNs, and 5 myxopapillary (Myxo) EPNs. Transcriptomic profiles from each sample were interrogated using the Human Genome U133plus2
Array (Affymetrix) platform as described previously. 10 Posterior fossa EPN subgrouping was determined using nonnegative matrix factorization clustering analysis as previously described. 12 Supratentorial EPN subgrouping was determined using signature transcript genes, ADP ribosylation factor like GTPase 4D (ARL4D; Probeset ID#203586), claudin 1 (CLDN1; 222549), RELA (201783), L1-celladhesion molecule (L1CAM; 204584) as described by Patjler et al. 3 We then validated these findings by examining RELA fusion protein in a subset of the characterized samples by the western blot analysis. From this transcriptomic dataset we extracted PD-L1 (CD274, Geneprobe #227458) to identify association of PD-L1 expression with the respective EPN subtypes. These results were validated in part using an independent cohort of patients with EPN. 3 We then extrapolated gene expression of PD-L1 from all pediatric and adult tumors in our expanded cohort, which includes 9 diffuse 
Western immunoblots
Lysates were extracted from 9 ST-RELA, 2 ST-YAP, 13 Group A, 9
Group B, and 6 Normal brain samples. Primary antibodies used for pro- 
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were stained using the standard immunohistochemical techniques for CD4 and CD8 and cell numbers per high-power field were scored as previously described. 10 PD-L1 was performed using rabbit monoclonal PD-L1/CD274 (SP263) antibody (Ventana/Spring Bioscience). The antibody was used according to the manufacturer's protocol. For PD-L1, a subjective scoring 
Flow cytometry
Samples of patients with EPN were mechanically dissociated into single cell suspensions and viably frozen as previously described. 9 Cells were gently thawed and suspended in PBS supplemented with 10% FBS. Myeloid cells were distinguished from tumor cells by co-expression of CD45 and CD11b as described previously. 9 PD-L1 (eBiosciences, catalog number: 25-5983, Clone: MIH1) staining was measured on both myeloid cells and tumor. Myeloid and T-cell characterization was performed as previously described. 9 Flow cytometry was performed using a BD Gallios equipped with 561 laser, and flow data was analyzed using FloJo v10.7. 
T-cell exhaustion assay
Methylation array
DNA was isolated from snap frozen tumor specimen using All Prep DNA/RNA isolation kit (Qiagen). DNA methylation was assessed using the Infinium R MethylationEPIC BeadChip (Illumina). DNA (750 ng) per sample were submitted for bisulfite conversion using Zymo EZ DNA Methylation kits (Zymo Research Corp). Following the manufacturer's protocol, bisulfide deoxyribonucleic acid was amplified, fragmented, and hybridized to BeadChips. The chips were stained and then read with an iScan (Illumina), generating IDAT files to be used in subsequent statistical analyses. IDAT files were batch normalized and background corrected using default settings of the R package ChAMP. The absolute value was calculated across probes located within and near the promoter and gene body of PD-L1.
Statistical analysis
Statistical analyses were performed using R bioinformatics, Prism (GraphPad v6), and Excel (Microsoft) software. For all tests, statistical significance was defined as P < 0.05 using the Student t-test.
RESULTS
Characterization of supratentorial EPN subtypes
In order to identify EPN subtype specific PD-L1 expression, EPN samples were divided into the three molecular subtypes using negative matrix factorization clustering of gene expression profiles: Supratentorial, Group A and Group B EPN, as previously described. 13 We further characterized the 12 supratentorial patients with EPN in order to identify the common C11orf95-RELA translocation or YAP1 fusion.
We utilized a subtype associated signature geneset to distinguish ST-RELA translocation samples from ST-YAP fusion samples. 3 We ana- Fig. S1B ). Finally, we measured RELA protein levels across the 12 supratentorial and posterior fossa tumors in order to confirm the presence of the RELA fusion gene. In the patients with ST-RELA subtype geneset expression, we were able to validate the fusion protein at 100kDa by the western blot ( Supplementary   Fig. S1C ). With the proper characterization of our EPN samples, we were then able to perform the subsequent PD-L1/PD-1 analyses.
PD-L1 transcript levels are highest in RELA tumors
PD-L1 expression can be used to identify patients with lung cancer and melanoma that are more likely to benefit from checkpoint inhibitors such as pembroluzimab or nivolumab. 14 Group B (21 primary Group B and 8 Group B recurrent) patients (Fig. 1A) . ST-RELA patients have significantly higher levels of PD-L1 than Group A and B patients, and trended toward significance in comparison to our limited cohort of ST-YAP patients. We validated our cohort findings with an independent PD-L1 transcription analysis in a larger EPN transcriptomic cohort (Fig. 1B) . 3 In this cohort, RELA expression levels were significantly higher than in ST-YAP and Group A patients. The discrepancy in PFB_1 mRNA expression between our cohort and the validation cohort may come down to a difference in the utilization of subtyping technologies between It has been shown that differential DNA methylation across the EPN molecular subtypes results in unique gene expression profiles. We evaluated whether DNA methylation affects the PD-L1 transcription in ST-RELA using Illumina 850K methylation array. We found there was no differential methylation in the 12 probes that span the promoter region of PD-L1 across all of our patient samples with EPN (Supplementary Fig. S2 ). This suggests that PD-L1 expression in EPN is regulated by a mechanism other than methylation of the specific promoter region of the gene.
PD-L1 protein expression is highest in RELA
In previous studies, we have shown that microarray expression can be used to predict protein expression. 15, 16 To ensure our PD-L1 gene expression correlated with protein levels, we used lysates from snap frozen patient samples from available ST-RELA, ST-YAP, Group A, Group B, and normal brain. We found that PD-L1 protein levels were higher in ST-RELA tumors compared to patients from other EPN subtypes ( Figs. 2A and 2B ). Protein levels, as measured by densitometry, correlated very strongly with gene expression levels across EPN subtypes.
Involvement in clinical trials for PD-1/PD-L1 blockade requires
IHC-positive staining for PD-L1, thus, we tested and scored eight pediatric EPN paraffin-fixed tissues (four ST-RELA, two Group A, and two Group B). All ST-RELA tumors tested positive for PD-L1 (Fig. 3) . Two ST-RELA tumors tested had diffuse strong staining (score 3; Fig. 3A) , or high positivity, one had medium positivity (score 2; Fig. 3B ) and one had low positivity (score 1; Fig. 3C) , with patchy staining. All four Table S1 ), PD-L1 transcript may therefore provide a valuable surrogate for determination of PD-L1 protein levels for clinical trial selection. We therefore examined PD-L1 gene expression in our transcriptomic dataset containing the majority of pediatric and some adult brain tumor types. We established a minimum expression level of 3 as our cutoff, as this represents a value double the background level in our microarray data (Supplementary Fig. S3 ). We were able to see bands on our western blots at expression levels as low as 2.49, but chose 3 as our cut off in order to be more stringent. From this cutoff we determined the percent of PD-L1-positive patient tumor samples for each tumor type that was further subdivided by either molecular subtype or anatomic location within the CNS (Fig. 4) . This analysis showed that Adamantinomatous Craniopharyngioma, low grade Astrocytomas, and some high grade Astrocytomas expressed PD-L1 at levels equal to or higher than ST-RELA, whereas some other common tumor types, in particular Medulloblastomas and Diffuse Intrinsic Pontine Gliomas, showed no PD-L1 expression. These data suggest that PD-L1 transcript can be helpful in determining which patients would be candidates for future clinical trials, although this would require some protein expression validation.
PD-L1 found on both tumor and myeloid cells in RELA
It is known that PD-L1 can be upregulated by either tumor cells or myeloid cells. Given that EPNs have significant infiltration of immune 
T cells in RELA tumors express high levels of PD-1 and are exhausted
We have previously shown that T-cell infiltration, specifically CD4 infiltration, correlated with outcome in tumors with EPN, but its association with EPN molecular subtypes was not evaluated. 16 We therefore measured T-cell infiltration in ST-RELA, Group A and Group B tumors with EPN by IHC. We found that ST-RELA tumors had significantly more CD4 infiltration than either posterior fossa subtype (Fig. 6A) .
CD8 infiltration was also significantly higher in ST-RELA tumors compared to Group B, but not when compared to Group A (Fig. 6A) .
T-cell PD-1 interaction with tumor or myeloid PD-L1 results in inhibition of T-cell proliferation and subsequent T-cell exhaustion. T-cell exhaustion is one of the mechanisms by which tumors evade immunemediated clearance. 4 In order to identify if this immune suppressive mechanism was present in pediatric EPN subtypes, we measured PD-1 levels on both CD4 and CD8 EPN infiltrating T cells by flow cytometry (Supplementary Fig. S5 ). We found that ST-RELA do in fact express PD-1 on both of their infiltrating T-cell populations (Fig. 6B) . We also found the same to be true for Group A and B tumor samples.
Using a functional T-cell exhaustion assay, earlier studies by our group had showed that Group A infiltrating T cells were unable to induce cytokine secretion in response to a nonspecific stimulus in comparison to Group B. 10 In order to evaluate whether ST-RELA (Fig. 6C) . These findings in ST-RELA suggest that tumor evasion and immunosuppression is due to PD-L1/PD-1-mediated T-cell exhaustion. In Group A tumors, we found high levels of PD-1 on both subsets of T cells (Fig. 6B) . Similar to the ST-RELA tumors, the T cells in Group A tumors were unable to produce a significant level of IFN-in response to PMA/ionomycin suggesting the T cells are also exhausted (Fig. 6C) . However, given we found very little PD-L1 in Group A tumors, it is likely the mechanism of T-cell exhaustion is due to the previously described Group A inflammatory microenvironment driven by tumor secreted IL-6. 12 On investigation of IL-6 secretion across EPN subtypes, we found that Group A secretes significantly higher amounts of IL-6 than any other subtype and ST-RELA tumors do not secrete IL-6 at all (Supplementary Fig. S6 ). Group B T-cells also expressed high levels of PD-1, however both CD4 and CD8 T cells were able to secrete IFN-after PMA/Ionomycin stimulation, which indicates that PD-1 levels are due to normal T-cell antigenactivation, as has been a documented function of PD-1. 6 
DISCUSSION
EPN is an aggressive childhood brain tumor with poor survival and significant long-term morbidity. The standard therapy has not changed in two decades and consists of surgery and radiation. Chemotherapy and small molecule inhibitors have failed and up to half the children with EPN will relapse within a decade and almost all of these relapsed patients will die. 17 There is a vital need for novel therapeutic approaches for these very high risk patients. Given the recent successes of immunotherapy, such as the PD-1 checkpoint inhibitor studies in adult cancers, this approach should be explored in resistant brain tumors. 18 Careful selection of pediatric populations to test these agents is paramount if the agents are to be successfully introduced in the resistant tumors of childhood. Pediatric tumors are rarer and generally have less mutational load than those of adults. 19 It is also thought, that due to this generally decreased mutational load, immune checkpoint inhibitors would be less effective. 20 It is apparent from our data that there may be significant differences in PD-L1 expression status even between subtypes of a tumor. Chromothrypsis, and thus mutational load, identified in ST-RELA tumors may result in increased neoantigen expression. 21 The relatively high level of neoantigens in ST-RELA may underlie the exhausted T-cell phenotype inferred by PD-L1 expression in these tumors. Lastly, NF-kB activity has been implicated as a driver of PD-L1 expression in melanoma. 22 Collectively, these data provide optimism that ST-RELA might be responsive to immune checkpoint inhibitors. 23 In our study, we showed that expression of PD-1 on the T cells, and PD-L1 on the myeloid and tumor cells was common among the ST-RELA fusion subtype but uncommon in the other three types of trial given the data about the predictive value of PD-L1. 8 Questions remain how reliable PD-L1 expression is in predicting response to a PD-1 inhibitor and whether the level of PD-L1 expression or protein is important, although currently PD-L1 expression remains the best predictor of response to PD-1 inhibitor therapy. 14, 24 Our data also show that T cells isolated from ST-YAP fusion tumors and Group A tumors are also nonresponsive ex vivo and do not produce inflammatory cytokines. Yet these tumors lack PD-L1, and a PD-1 interaction with PD-L1 does not explain why the T cells are functionally exhausted in these tumors. This is in comparison to the Group B tumors with functional T cells and excellent clinical outcomes. 10 This would suggest that while PD-1 inhibitors would be reasonable to try in ST-RELA, an alternative immunotherapy approach may be necessary in ST-YAP and Group A tumors. Indeed, our previous work would suggest that an immunotherapy approach to Group A may involve inhibiting an IL-6/myeloid interaction. 12 We know from previous work that the variation in immunobiology among different childhood brain tumors is profound and this paper and others from our group document that this extends into tumor subtypes. Extending our understanding of differing immunobiology among tumors and their subtypes is necessary in order to provide better clinical care, maximizing personalized medicine and rational treatment for these patients.
A technical point from our observations in this study may help enrich patients likely to respond to a particular immunotherapy. We This study investigated the presence of PD-L1 in EPN by IHC. There is presently some difficulty surrounding the use of this technique to interpret PD-L1 in EPN, as identified by a recent study. 25 Despite these problems, their study concluded that PD-L1 was absent in all pediatric EPN. In contrast, our study clearly identified the presence of PD-L1 in supratentorial RELA EPN. Importantly, the antibody used was recently described as highly reliable. 26 These results enhance the rigor and reliability of this study. In conclusion, any PD-1 inhibitor therapy trial, if conducted in EPN should be enriched for relapsed ST-RELA tumors.
Alternative immunotherapies should be developed for the other subtypes of EPN with functionally exhausted T cells but without evidence of PD-L1 expression on myeloid or tumor cells.
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